Citalopram: A review of its pharmacology, clinical efficacy and tolerability in the treatment of depression

CNS Drugs

Volumn 8, Issue 5, 1997, Pages 410-431

  Noble, Stuart ^a   Benfield, Paul ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; CITALOPRAM; CLOMIPRAMINE; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; MAPROTILINE; MIANSERIN; NEUROLEPTIC AGENT; NORCITALOPRAM; NORTRIPTYLINE; PAROXETINE; SEROTONIN; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TETRACYCLIC ANTIDEPRESSANT AGENT; TRICYCLIC ANTIDEPRESSANT AGENT;

AGING; ANOREXIA; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG COST; DRUG ELIMINATION; DRUG MECHANISM; DRUG OVERDOSE; DRUG RECEPTOR BINDING; DRUG TOLERABILITY; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; META ANALYSIS; MULTICENTER STUDY; NAUSEA; ORAL DRUG ADMINISTRATION; ORTHOSTATIC HYPOTENSION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; SEXUAL DYSFUNCTION; TACHYCARDIA; VOMITING; WEIGHT GAIN; XEROSTOMIA;

EID: 0030727889     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-199708050-00009     Document Type: Review

References (103)

1. Wade AG, Lepola U, Koponen HJ, et al. The effect of citalopram in panic disorder. Br J Psychiatry 1997 Jun; 170 (6): 549-53
2. Lepola U, Leinonen E, Turtonen J, et al. The effect of citalopram in panic disorder and agoraphobia: a pilot study [abstract]. Psychopharmacology 1993 Apr; 111: B7
3. Humble M, Wistedt B. Serotonin, panic disorder and agoraphobia: short-term and long-term efficacy of citalopram in panicdisorders. Int Clin Psychopharmacol 1992 Jun; 6 Suppl. 5: 21-39
4. Nyth AL, Gottfries CG. The clinical efficacy of citalopram in treatment of emotional disturbances in dementia disorders: a Nordic multicentre study. Br J Psychiatry 1990 Dec; 157: 894-901
5. Vartiainen H, Tiihonen J, Putkonen A, et al. Citalopram, a selective serotonin reuptake inhibitor, in the treatment of aggression in schizophrenia. Acta Psychiatr Scand 1995; 91: 348-51
6. Andersen G, Vestergaard K, Rils JO. Citalopram for post-stroke pathological crying. Lancet 1993 Oct 2; 342: 837-9
7. Hyttel J, Bogeso KP, Perregaard J, et al. The pharmacological effect of citalopram resides in the (S)-(+)-enantiomer. J Neural Transm Gen Sect 1992; 88 (2): 157-60
8. Goodwin CM. How do antidepressants affect serotonin receptors? The role of serotonin receptors in the therapeutic and side effect profile of the SSRIs. J Clin Psychiatry 1996; 57 Suppl. 4: 9-13
9. Morel C, Briley M. Effects of acute and repeated administration of citalopram on extracellular levels of serotonin in rat brain. Eur J Pharmacol 1996; 295: 189-97
10. Auerhach SB, Hjorth S. Effect of chronic administration of the selective serotonin (5-HT) uptake inhibitor citalopram on extracellular 5-HT and apparent autoreceptor sensitivity in rat forebrain in vivo. Naunyn Schmiedebergs Arch Pharmacol 1995; 352: 597-606
11. IA receptor antagonist (S)-UH-301 augments the increase in extracellular concentrations of 5-HT in the frontal cortex produced by both acute and chronic treatment with citalopram. Naunyn Schmiedebergs Arch Pharmacol 1996; 353: 630-40
12. IA autoreceptors and the mode of action of selective serotonin reuptake inhibitors (SSRI). Behav Brain Res 1996; 73: 281-3
13. IA receptor antagonists increase the activity of serotonergic cells in the dorsal raphe nucleus in rats treated acutely or chronically with citalopram. Naunyn Schmiedebergs Arch Pharmacol 1995; 352: 157-65
14. Milne RJ, Goa KL. Citalopram: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depressive illness. Drugs 1991 Mar; 41: 450-77
15. Hyttel J. Pharmacological characterization of selective serotonin reuptake inhibitors (SSRIs). Int Clin Psychopharmacol 1994 Mar; 9 Suppl. 1: 19-26
16. Richelson E, Pfenning M. Blockade by antidepressants and related compounds of biogenic amine uptake into rat brain synaptosomes: most antidepressants selectively block norepinephrine uptake. Eur J Pharmacol 1984; 104: 277-86
17. Hyttel J. Citalopram - pharmacological profile of a specific serotonin uptake inhibitor with antidepressant activity. Prog Neuropsychopharmacol Biol Psychiatry 1982; 6: 277-95
18. Richelson M, Nelson A. Antagonism by antidepressants of neurotransmitter receptors of normal human brain in vitro. J Pharmacol Exp Ther 1984; 230 (1): 94-102
19. Hall H, Sallemark M, Wedel I. Acute effects of atypical antidepressants on various receptors in the rat brain. Acta Pharmacol Toxicol Copenh 1984 May; 54: 379-84
20. Hyttel J, Arnt J, Sánchez C. The pharmacology of citalopram Rev Contemp Pharmacother 1995; 6 (6): 271-85
21. Hyttel J, Overø KF, Arnt J. Biochemical effects and drug levels in rats after long-term treatment with the specific 5-HT-uptake inhibitor, citalopram. Psychopharmacology (Berl) 1984; 83: 20-7
22. Garcha G, Smokcum RW, Stephenson JD, et al. Effects of some atypical antidepressants on β-adrenoceptor binding and adenylate cyclase activity in the rat forebrain. Eur J Pharmacol 1985 Jan 15; 108: 1-7
23. Luo H, Richardson JS. A pharmacological comparison of citalopram, a bicyclic serotonin selective uptake inhibitor, with traditional tricyclic antidepressants. Int Clin Psychopharmacol 1993; 8 (1): 3-12
24. Vetulani J, Antkiewicz-Michaluk L, Rokosz-Pelc A. Chronic-administration of antidepressant drugs increases the density of cortical [3H]prazosin binding sites in the rat. Brain Res 1984 Sep 24; 310: 360-2
25. 4 receptors in rats. Naunyn Schmiedebergs Arch Pharmacol 1997; 356: 22-8
26. 2 dopamine receptor binding in humans measured with positron emission tomography. Psychopharmacology 1996; 126: 277-80
27. Christensen AV, Fjalland B, Pedersen V, et al. Pharmacology of a new phthalane (Lu 10-171), with specific 5-HT uptake inhibiting properties. Eur J Pharmacol 1977; 41: 153-62
28. Fairweather DB, Dal Pozzo C, Kerr JS, et al. Citalopram compared to dothiepin and placebo: effects on cognitive function and psychomotor performance. Hum Psychopharmacol 1997; 12: 119-26
29. Sindrup SH, Brosen K, Hansen MG, et al. Pharmacokinetics of citalopram in relation to the sparteine and the mephenytoin oxidation polymorphisms. Ther Drug Monit 1993 Fob; 15: 11-7
30. Crewe HK, Lennard MS, Tucker GT, et al. The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes. Br J Clin Pharmacol 1992 Sep; 34: 262-5
31. Skjelbo E, Brosen K. Inhibitors of imipramine metabolism by human liver microsomes. Br J Clin Pharmacol 1992 Sep; 34: 256-61
32. Jeppesen U, Gram LF, Vistisen K, et al. Dose-dependent inhibition of CYPIA2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine. Eur J Clin Pharmacol 1996; 51: 73-8
33. Priskorn M, Larsen F, Segonzac A, et al. Pharmacokinetic interaction study of citalopram and cimetidine in healthy subjects. Eur J Clin Pharmacol 1997; 52: 241-2
34. Kragh-Sørensen P, Ovenø KF, Petersen OL, et al. The kinetics of citalopram: single and multiple dose studies in man. Acta Pharmacol Toxicol Copenh 1981 Jan; 48: 53-60
35. . Citalopram Product Monograph, H. Lundbeck A/S, 1994
36. Overø KF. Preliminary studies of the kinetics of citalopram in man. Eur J Clin Pharmacol 1978 Nov 9; 14: 69-73
37. de-Wilde J, Mertens C, Overø KF, et al. Citalopram versus mianserin: a controlled, double-blind trial in depressed patients. Acta Psychialr Scand 1985 Jul; 72: 89-96
38. Bouchard JM, Delaunay J, Delisle JP, et al. Citalopram versus maproliline: a controlled, clinical mullicentre trial in depressed patients. Acta Psychiatr Scand 1987 Nov; 76: 583-92
39. Gravem A, Amthor KF, Astrup C, et al. A double-blind comparison of citalopram (Lu 10-171) and amitriptyline in depressed patients. Acta Psychiatr Scand 1987 May; 75: 478-86
40. Ahlfors UG, Elovaara S, Harma P, et al. Clinical mullicentre study of citalopram compared double-blindly with mianserin in depressed patients in Finland. Nord Psykiatr Tidsskr 1988; 42: 201-10
41. OverØ KF. Kinetics of citalopram in man; plasma levels in patients. Prog Neuropsychopharmacol Biol Psychiatry 1982; 6: 311-8
42. Bjerkenstedt L, Flyckt L, Overø KF, et al. Relationship between clinical effects, serum drug concentration and serotonin uptake inhibition in depressed patients treated with citalopram: a double-blind comparison of three dose levels. Eur J Clin Pharmacol 1985; 28: 553-7
43. Baumann P, Larsen F. The pharmacokinetics of citalopram. Rev Contemp Pharmacother 1995; 6 (6): 287-95
44. Leinonen E, Lepola U, Koponen H, et al. The effect of age and concomitant treatment with other psychoactive drugs on serum concentrations of citalopram measured with a nonenanlioselective method. Ther Drug Monit 1996; 18: 111-7
45. Rochat B, Amey Y, Baumann P. Analysis of enantiomers of cilalopram and its demethylated metabolites in plasma of depressive patients using chiral reverse-phase liquid chromatography. Ther Drug Monit 1995; 17: 273-9
46. Rochat B, Amey H, Van Gelderen H, et al. Determination of the enantiomers of cilalopram, its demethylated and propionic acid metabolites in human plasma by chiral HPLC. Chirality 1995; 7: 389-95
47. Kobayashi K, Yamamoto T, Chiba K, et al. The effects of selective serotonin reuptake inhibitors and their metabolites on S-mephenytoin 4′-hydroxylase activity in human liver microsomes. Br J Clin Pharmacol 1995; 40: 481-5
48. Kobayashi K, Chiba K, Yagi T, et al. Identification of cytochrome P450 isoforms involved in citalopram N-demethyla- tion by human liver microsomes. J Pharmacol Exp Ther 1997; 280 (2): 927-33
49. Rudorfer MV, Polier WZ. Pharmacokinelics of antidepressants. In: Meltzer HY, editor. Psychopharmacology: the third generation of progress. New York: Raven Press, 1987: 1353-63
50. Øyehaug E, Østensen ET, Salvesen B. High-performance liquid Chromatographic determination of cilaloprarn and tour of its metabolites in plasma and urine samples from psychiatric patients. J Chromatogr 1984 Jun 8; 308: 199-208
51. Overø KF, Toft B, Christophersen L, et al. Kinetics of citalopram in elderly patients. Psychopharmacology 1985; 86: 253-7
52. Foglia JP, Pollock BG, Kirshner MA, et al. Psychopharmacology in geriatric populations. Psychopharmacol Bull 1997; 33 (1): 109-12
53. Syvälahti EKG, Taiminen T, Saarijärvi S, et al. Cilalopram causes no signifient alterations in plasma neuroleptic levels in schizophrenic patients. J Int Med Res 1997 Jan/Feb; 25 (1): 24-32
54. Baettig D, Bondolfi G, Montaldi S, et al. Tricyclic antidepressant plasma levels after augmentation with citalopram: a case study. Eur J Clin Pharmacol 1993; 44 (4): 403-5
55. Gram LF, Hansen MGJ, Sindrup SH, et al. Citalopram: interaction studies with levomepromazine, imiprainine, and lithium. Ther Drug Monit 1993 Feb; 15: 18-24
56. Bondolfi G, Chaulems C, Rochat B, et al. Non-response to citalopram in depressive patients: pharmacokinetic and clinical consequences of a fluvoxamine augmentation. Psychopharmacology 1996; 128: 421-5
57. Priskhorn M, Sidhu JS, Larsen F, et al. Investigation of multiple dose citalopram on the pharmacokinetics and pharmacodynamics of racemic warfarin. Br J Clin Pharmacol 1997; 44: 199-202
58. Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 1967; 6: 278-96
59. Montgomery SA, Asberg M. A new depression scale designed lobe sensitive to change. Br J Psychiatry 1979; 134: 382-9
60. Guy W, editor. ECDEU assessment manual for psychopharmacology. Clinical Global Impressions (028-CGI). Washington. DC: USGPO, 1976
61. Feighner J, Overø K, Fieve R, et al. Fixed dose comparison of citalopram versus placebo in the treatment of outpatients with moderate to severe depression [poster no. 419]. Presented at 150th Annual Meeting, American Psychiatric Association; 1997; San Diego
62. Mendels J, Overø K, Kiev A, et al. Citalopram versus placebo in the treatment of outpatients with moderate to severe depression [poster no. 465]. Presented at 150th Annual Meeting, American Psychiatric Association; 1997; San Diego
63. Andersen G, Veslergaard K, Lauritzen L. Effective treatment of poststroke depression with the selective serotonin reuptake inhibitor citalopram. Stroke 1994 Jun; 25: 1099-104
64. Montgomery SA, Rasmussen JGC, Lyby K. Dose response relationship of citalopram 20mg. citalopram 40mg and placebo in the treatment of moderate and severe depression. Int Clin Psychopharmacol 1992 Jun; 6 Suppl. 5: 65-70
65. Nyth AL, Gottfries CG, Lyby K, et al. A controlled multicenter clinical study of citalopram and placebo in elderly depressed patients with and without concomitant dementia. Acta Psychiatr Scand 1992 Aug; 86: 138-45
66. Bech P, Cialdella P. Citalopram in depression - meta-analysis of intended and unintended effects. Int Clin Psychopharmacol 1992 Jun; 6 Suppl. 5: 45-54
67. Montgomery SA, Pedersen V, Tanghøj P, et al. The optimal dosing regimen for citalopram - a meta-analysis of nine pla- cebo-controlled studies. Int Clin Psychopharmacol 1994 Mar; 9 Suppl. 1: 35-40
68. Baumann P, Nil R, Souche A, et al. A double-blind, placebo-controlled study of citalopram with and without lithium in the treatment of therapy-resistant depressive patients: a clinical, pharmacokinetic, and pharmacogenetic investigation. J Clin Psychopharmacol 1996; 16: 307-14
69. Montgomery SA, Rasmussen JG, Tanghoj P. A 24-week study of 20mg citalopram, 40mg citulopram, and placebo in the prevention of relapse of major depression. Int Clin Psychopharmacol 1993 Fall; 8: 181-8
70. Robert P, Montgomery SA. Citalopram in doses of 20-60mg is effective in depression relapse prevention: a placebo-controlled 6 month study. Int Clin Psychopharmacol 1995; 10 Suppl. 1: 29-35
71. Shaw DM, Thomas DR, Briscoe MH, et al. A comparison of the antidepressant action of citalopram and amitriptyline. Br J Psychiatry 1986 Oct; 149: 515-7
72. Danish University Antidepressant Group. Citalopram: clinical effect profile in comparison with clomipramine: a controlled multicenter study. Psychopharmacology 1986; 90: 131-8
73. Rosenberg C, Damsbo N, Fuglum E, et al. Citalopram and imipramine in the treatment of depressive patients in general practice: a Nordic multicentre clinical study. Int Clin Psychopharmacol 1994 Mar; 9 Suppl. 1: 41-8
74. Timmerman L, de Beurs P, Tan BK, et al. A double-blind comparative clinical trial of citalopram vs maprotiline in hospitalized depressed patients. Int Clin Psychopharmacol 1987 Jul; 2: 239-53
75. Anderson IM, Tomenson BM. The efficacy of selective serotonin re-uptake inhibitors in depression: a meta-analysis of studies against tricyclic antidepressants. J Psychopharmacol 1994; 8 (4): 238-49
76. Nuijten MJC, Hardens M, Souêtre E. A Markov process analysis comparing the cost effectiveness of maintenance therapy with citalopram versus standard therapy in major depression. Pharmacoeconomics 1995; 8 (2): 159-68
77. Patris M, Bouchard J-M, Bougerol T, et al. Citalopram versus fluoxetine: a double-blind, controlled, multicentre, phase III trial in patients with unipolar depression treated in general practice. Int Clin Psychopharmacol 1996; 11: 129-36
78. Bougerol T, Scotto J-C, Patris M, et al. Citalopram and fluoxetine in major depression: comparison of two clinical trials in a psychiatrist setting and in general practice. Clin Drug Invest. In press
79. Haffmans PMJ, Timmerman L, Hoogduin CAL, et al. Efficacy and tolerability of citalopram in comparison with fluvoxamine in depressed outpatients: a double-blind, multicentre study. Int Clin Psychopharmacol 1996; 11: 157-64
80. Dencker SJ, Petersen HEH. Side-effect profile of citalopram and reference antidepressants in depression. XXII Nordiske Psykiater-Kongres; 1988 Aug 10-13; Reykjavik, 31-42
81. Baldwin D, Johnson FN. Tolerability and safety of citalopram. Rev Contemp Pharmacother 1995; 6 (6): 315-25
82. Rudorfer MV, Manji HK, Potter WZ. Comparative tolerability profiles of the newer versus older antidepressants. Drug Saf 1994 Jan; 10: 18-46
83. Lauerma H. Successful treatment of citalopram-induced anorgasmia by cyproheptadine. Acta Psychiatr Scand 1996; 93: 69-70
84. Michael A, Herrod JJ. Citalopram-induced decreased libido [letter]. Br J Psychiatry 1997 Jul; 171: 90
85. Berk M, Acton M. Citalopram-associated clitoral priapasm: a case series. Int Clin Psychopharmacol 1997; 12: 121-2
86. Bouwer CD, Harvey BH. Phasic craving for carbohydrate observed with citalopram. Int Clin Psychopharmacol 1996; 11: 273-8
87. Risby E, Donnigan D, Nemeroff C. Pharmacotherapeutic considerations for psychiatric disorders: depression. Formulary 1997 Jan; 32: 46-59
88. Østrom M, Erikkson A, Thorson J, et al. Fatal overdose with citalopram [letter]. Lancet 1996 Aug 3; 348: 339-40
89. Grundemar L, Wohlfart B, Lagerstedt C, et al. Symptoms and signs of severe citalopram overdose. Lancet 1997 May 31; 349: 1602
90. Personne M, Persson H, Sjöberg G. Citalopram toxicity [letter]. Lancet 1997 Aug 16; 350: 518-9
91. Neuvonen PJ, Pohjola-Sintonen S, Tacke U, et al. Five fatal cases of serotonin syndrome after moclobemide-citalopram or moclobemide-clomipramine overdoses. Lancet 1993 Dec 4; 342: 1419
92. Greenberg PE, Stiglin LE, Finkelstein SN, et al. The economic burden of depression in 1990. J Clin Psychiatry 1993 Nov; 54: 405-18
93. Kessler RC, McGonagle KA, Zhao S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Arch Gen Psychiatry 1994 Jan; 51: 8-19
94. Broadhead WE, Blazer DG, George LK, et al. Depression, disability days, and days lost from work in a prospective epidemiological survey. JAMA 1990 Nov 21; 264: 2524-8
95. Kupfer DJ. Long-term treatment of depression. J Clin Psychiatry 1991 May; 52 (5 Suppl.): 28-34
96. Hirschfeld RMA. Long-term drug treatment of unipolar depression. Int Clin Psychopharmacol 1996; 11: 211-7
97. Cohen LJ. Rational drug use in the treatment of depression. Pharmacotherapy 1997; 17 (1): 45-61
98. Sussman N, Stahl S. Update in the pharmacotherapy of depression. Am J Med 1996 Dec 30; 101 Suppl. 6A: 26S-36S
99. de Jonghe F, Swinkels J. Selective serotonin reuptake inhibitors: relevance of differences in their pharmacological and clinical profiles. CNS Drugs 1997 Jun; 7 (6): 452-67
100. van den Berg SJ. Comparing SSRIs: from chemistry to clinical choice. Hum Psychopharmacol 1995; 10: S199-209
101. van-Harten J. Clinical pharmacokinetics of selective serotonin reuptake inhibitors. Clin Pharmacokinet 1993 Mar; 24: 203-20
102. Baumann P, Rochat B. Comparative pharmacokinetics of selective serotonin reuptake inhibitors: a look behind the mirror. Int Clin Psychopharmacol 1995; 10 Suppl. 1: 15-21
103. Brøsen K. The pharmacogenetics of the selective serotonin reuptake inhibitors. Clin Investig 1993 Dec; 71: 1002-9